By Colin Kellaher

AbbVie has struck a pair of exclusive option and license agreements with clinical-stage biotechnology company Umoja Biopharma aimed at developing new chimeric antigen receptor T-cell, or CAR-T, cancer therapy candidates.

AbbVie on Thursday said the companies plan to develop multiple in-situ generated CAR-T cell therapy candidates using Umoja's proprietary VivoVec platform.

AbbVie said it made upfront payments and an equity investment in Umoja, which is eligible to receive up to $1.44 billion for option exercise fees, development and regulatory milestones, along with additional sales-based milestones and royalties on sales.

AbbVie said it has an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates, including Umoja's lead clinical program for hematologic malignancies, which is currently at the IND-enabling phase.

The companies also plan to develop up to four additional candidates for discovery targets selected by AbbVie, based in North Chicago, Ill.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 04, 2024 09:14 ET (14:14 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos AbbVie.
AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos AbbVie.